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Abstract 27 
Objectives  28 
To report and compare early oncological outcomes and cancer recurrence sites among 29 
patients undergoing open radical cystectomy (ORC) and robotic assisted radical 30 
cystectomy with intracorporeal urinary diversion (iRARC).  31 
 32 
Methods and materials 33 
184 patients underwent radical cystectomy for bladder cancer. ORC cases (n=94) were 34 
performed between June 2005- July 2014 while iRARC cases (n=90) were performed 35 
between June 2011- July 2014. Primary outcome was recurrence free survival (RFS). 36 
Secondary outcomes were sites of local and metastatic recurrence and overall survival 37 
(OS). 38 
 39 
Results 40 
Median follow-up for patients without recurrence was 33.8 months (IQR: 20.5-45.4) for 41 
ORC; and 16.1 months (IQR: 11.2-27.0) for iRARC. No significant difference in age, 42 
gender, pre-cystectomy T stage, pre-cystectomy grade, or lymph node yield between 43 
ORC and iRARC was observed. The ORC cohort included more patients with ≥pT2 44 
(64.8% ORC vs 38.9% iRARC) but fewer pT0 status (8.5% ORC vs 22.2% iRARC) due 45 
to lower preoperative chemotherapy use (22.3% ORC vs 34.4% iRARC). Positive 46 
surgical margin rate was significantly higher in the ORC cohort (19.3% vs 8.2%; 47 
p=0.042). Kaplan-Meir analysis showed no significant difference in RFS (69.5% ORC vs 48 
78.8% iRARC), CSS (80.9% ORC vs 84.4% iRARC), or OS (73.5% ORC vs iRARC 49 
83.8%) at 24 months. Cox regression analysis showed RFS, CSS and OS were not 50 
influenced by cystectomy technique. No significant difference between local and 51 
metastatic RFS between ORC and iRARC was observed.  52 
 53 
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Conclusion  54 
This study has found no difference in recurrence patterns or oncological outcomes 55 
between ORC and iRARC. Recurrent metastatic sites vary, but are not related to 56 
surgical technique.  57 
Keywords 58 
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1. Introduction     77 
Radical cystectomy with lymphadenectomy remains the gold standard of curative 78 
treatment for muscle invasive or recurrent high grade non-muscle invasive bladder 79 
cancer (1). Minimally invasive radical cystectomy has evolved to include robotic 80 
assisted laparoscopic techniques with intracoporeal urinary diversion, largely as a result 81 
of developments in robotic technology, and in a number of centers has become the 82 
surgical approach of choice in selected cases (2-4).  83 
Evidence from retrospective case series that compare open radical cystectomy (ORC) 84 
to intracorporeal robotic assisted radical cystectomy (iRARC) reports that iRARC carries 85 
a lower risk of major complications and reduced transfusion rate (5). However, it is 86 
equally important that oncological outcomes following iRARC should at least be 87 
equivalent to ORC. It is also essential to determine if surgical technique influences the 88 
landing sites and pattern of recurrence following radical cystectomy.   89 
Although no studies exist that compare iRARC to ORC, a recent systematic review 90 
suggests that early oncological outcomes after RARC were comparable to ORC (6). To 91 
date, published studies reporting oncological outcomes after iRARC comprise largely of 92 
case series, with few studies comparing the outcomes of robotic and open surgery (7, 93 
8). Recently, in a series of 383 patients over 13 years, Nguyen et al. reported a larger 94 
proportion of extrapelvic lymph node metastasis and peritoneal carcinomatosis following 95 
RARC compared to ORC, although statistical significance was not reached (9). The 96 
authors found that RARC was not an independent predictor of recurrence after surgery 97 
(9). Non randomized comparative series have the potential for bias and, while a 98 
randomized controlled trail by Bochner et al. has been conducted comparing ORC and 99 
RARC, it was not designed to determine whether there is a survival benefit for RARC 100 
(10). The trial was intended to detect a reduction in Clavian grade 2-5 complication rate 101 
of ≥20% at 90 days but was closed early following a futility analysis. 102 
In this study, we report early oncological outcomes of 184 consecutive open or iRARC 103 
cases within a tertiary referral center. Secondary objectives included a comparison of 104 
local versus metastatic recurrence and overall survival (OS) for ORC and iRARC. 105 
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2. Material and methods  126 
2.1 Patient cohort 127 
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A retrospective analysis of 184 patients within a tertiary referral center underwent 128 
radical cystectomy for primary bladder cancer with curative intent. ORC cases (n=94) 129 
were performed from June 2005 to July 2014 while RARC cases (n=90) were performed 130 
from June 2011 to July 2014. Four cases were excluded based on the lack of 131 
histopathological data. Prior to 2013, RARC was performed at one of the two sites 132 
undertaking radical cystectomy. After 2013 all cystectomies were performed at one site. 133 
In 2014, 45 radical cystectomy cases were performed and in 2015 this increased to 63 134 
cases. All three surgeons performing open cystectomy had performed ≥100 cases 135 
previously and the two iRARC surgeons, who also performed the ORC cases, 136 
performed 76 and 14 iRARCs respectively during the study period.  137 
Inclusion criteria were patients with muscle invasive bladder cancer (MIBC) or high risk 138 
non-MIBC who had radical cystectomy and lymphadenectomy with curative intent. The 139 
type of urinary diversion was dependent on patient choice provided there were no 140 
absolute contraindications (11). All patients underwent preoperative laboratory 141 
investigations, cross sectional imaging for staging, and transurethral resection of 142 
bladder tumour (TURBT). Preoperative chemotherapy  was recommended for patients 143 
with MIBC who had an Eastern Cooperative Oncology Group (ECOG) performance 144 
score ≤1, glomerular filtration rate (GFR) ≥60mL/min and no contraindication. Three 145 
cycles of Gemcitabine-Cisplatin (Gem-Cis) was typically used if tolerated. The use of 146 
adjuvant chemotherapy or adjuvant radiotherapy was based on the decision of the 147 
tumor board meeting. 148 
The commencement of a robotic cystectomy program in June 2011 coincided with the 149 
start of the BOLERO trial, a phase II Cancer Research UK funded feasibility study on 150 
randomizing patients to ORC vs minimal invasive surgery (NCT01196403). At the start 151 
of the program, due to the expected learning curve, iRARC may have been avoided in 152 
comorbid patients. The number of iRARC cases increased year on year to 45.2%, 153 
83.3% and 97.8% of cystectomy cases in 2012, 2013 and 2014 respectively.    154 
 155 
2.2 Surgical technique 156 
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The standard technique for both ORC and iRARC has been described previously (4, 157 
12). iRARC was performed using a 6 port transperitoneal approach with the patient in 158 
27° Trendelenburg was used. Pelvic lymph node dissection included excision of 159 
obturator, external, internal and common iliac nodes. For RARC following cystectomy, 160 
the specimen was placed in an endocatch bag (Covidien, Dublin, Ireland) and removed 161 
after lymphadenectomy and urinary diversion were complete in males via the extended 162 
right iliac fossa port site, or via the vagina in females. The intracorporeal ileal conduit 163 
was constructed using 15 cm of terminal ileum, taken 15 cm from the ileo-cecal valve 164 
using a 60 mm laparoscopic intestinal stapler (Endo-GIA; Covidien, Dublin, Ireland). 165 
Intracorporeal continent diversion required 50 cm of terminal ilium which was 166 
detubularised and cross folded without an afferent limb. Uretero-ileal anastomosis was 167 
performed either using a Bricker (JDK) or a Wallace (TPB) anastomosis. 6F infant 168 
feeding tubes/ Bander stents were externalized and used as ureteric stents. 169 
 170 
2.3 Patient covariates  171 
Patient demographics, TURBT histopathology, radical cystectomy histopathology, type 172 
of surgery performed, neo-adjuvant chemotherapy (NAC) use and follow-up data were 173 
collected. Histopathological data included tumor type, grade (according to World Health 174 
Organization classification) (13), and tumor and nodal stage (according to 2002 TNM 175 
classification) (14). A positive surgical margin was defined as the presence of tumor at 176 
any soft tissue margin on the cystectomy specimen. 177 
Follow-up for all patients included imaging by CT scan of the chest, abdomen and pelvis 178 
at 6 months, 12 months and then annually. Additional imaging was based on presence 179 
of symptoms suggestive of recurrent disease or post-operative complications. Outcome 180 
measures included overall survival (OS), cancer specific survival (CSS) and recurrence 181 
free survival (RFS). Local recurrence was defined as any soft tissue or bony disease 182 
within the surgical bed, surgical incision site, pelvis and nodal disease below the aortic 183 
bifurcation and distant recurrence was defined as metastasis at any site outside the 184 
pelvis and nodal disease beyond the aortic bifurcation. Only cases of urothelial cell 185 
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carcinoma (UCC) were included in RFS, CSS and OS analysis as non-UCC patients 186 
have a different prognosis.  187 
2.4 Statistical analyses 188 
Descriptive statistics including mean, standard deviation, chi-square analysis and paired 189 
t test were used to report continuous and categorical data. Kaplan- Meier analysis was 190 
used to calculate survival probabilities and differences in survival were assessed using 191 
log-rank test analysis. Multivariable Cox regression analysis was performed to 192 
determine which variables were independent predictors of oncological outcomes. 193 
Statistical significance was set at p value ≤0.05. Statistical analysis was performed 194 
using SPSS v16 (IBM, New York, USA). 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
3. Results 206 
The overall median follow-up was 22.8 months (IQR: 12.5-35.6 months). The median 207 
follow-up for ORC and iRARC patients were 33.8 months (IQR: 20.5-45.4) and 16.1 208 
months (IQR: 11.2-27.0) respectively. There was no significant difference in age and 209 
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gender between ORC and iRARC although significantly more patients had a continent 210 
urinary diversion in the iRARC cohort (p=0.001).   211 
The majority of cases were UCC and there was no significant difference in pre-212 
cystectomy pathological T stage (Table 1). 31/90 patients (34.4%) in the iRARC group 213 
where received preoperative chemotherapy compared to 21/94 patients (22.3%) in the 214 
ORC cohort, which showed a trend towards statistical significance (X2=3.48, df=1 215 
p=0.073). There was no significant difference between the use of NAC (iRARC: 83.9% 216 
vs ORC: 71.4%) and inductive chemotherapy (iRARC: 16.1% vs ORC: 28.6%) in ORC 217 
and iRARC cohorts (p=0.281). 218 
The proportion of patients who were stage pT0 on post-operative histology was 219 
significantly higher in the iRARC cohort (iRARC: 22.2% vs ORC: 8.5%) (X2=5.540, df=1 220 
p=0.025) while positive soft tissue surgical margins were higher in the ORC cohort 221 
(iRARC: 8.2% vs ORC: 19.3) (X2=4.133, df=1 p=0.042). There was no significant 222 
difference between number of lymph nodes resected between ORC and RARC patients. 223 
Two ORC patients received postoperative radiotherapy, one for positive surgical margin 224 
and the other for isolated metastatic iliac nodal disease. Four iRARC patients had 225 
postoperative radiotherapy; one for positive surgical margin, two for an isolated sacral 226 
metastasis and a patient for an isolated port site recurrence. Two patients (2.1%) in the 227 
ORC cohort and 5 patients (5.6%) in the iRARC cohort received adjuvant chemotherapy 228 
while a further 5 patients (5.3%) and 4 patients (4.4%) in the ORC and iRARC cohort 229 
received palliative chemotherapy respectively.  230 
The analysis of RFS and OS was conducted on patients with UCC. There was no 231 
difference in RFS (65.9% ORC vs 75.2% iRARC), CSS (80.9% ORC vs 84.4% iRARC), 232 
or OS (72.5% ORC vs iRARC 79.2%) at 24 months (Figure 2-4). Propensity score 233 
adjustment for cystectomy pathological stage, lymph node status, use of preoperative 234 
chemotherapy and surgical margin status showed that there was no significant 235 
difference in recurrence free survival (p=0.210; OR: 0.58, 95% CI: 0.24-1.36), cancer 236 
specific survival (p=0.300; OR:0.62, 95% CI: 0.25-1.54) and overall survival (p=0.313; 237 
OR:0.64, 95% CIL 0.27-1.52) between ORC and iRARC.  238 
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Cox regression analysis showed that higher post-operative pathological stage and 239 
presence of nodal disease were independently associated with lower cancer RFS, CSS 240 
and OS (Table 2-4). Surgical technique was not significantly associated with RFS, CSS 241 
or OS. In addition, there was no difference in time to local recurrence [ORC (n=12): 242 
median: 8.4±13.0 months; IQR: 4.6-22.7 vs iRARC (n=10): median: 8.5±9.2 months; 243 
IQR: 4.1-16.1] or metastasis with/ without local recurrence [ORC (n=21): median: 244 
8.5±15.9 months; IQR: 3.9-19.1 vs iRARC (n=10): median: 6.4±10.4 months; IQR: 4.3-245 
17.9] (Figure 5A &4B). 246 
In the ORC cohort 30 patients (31.9%) had recurrence and 22 patients (23.4%) died as 247 
a result of recurrent disease. Three patients (3.6%) died 90 days post-operatively while 248 
a further 8 patients (9.5%) died from non-cancer causes. Nine patients had local 249 
recurrence alone, 13 patients had distant metastasis alone with 8 patients having both 250 
local and metastatic recurrence.  251 
In the iRARC group 17 patients (18.9%) developed recurrence which resulted in 11 252 
deaths (12.2%). One patient (1.3%) died 90 days postoperatively and two patients 253 
(2.5%) died from non-cancer causes. Among patients who had iRARC, 7 patients had 254 
local recurrence alone, while 6 patients had distant metastasis alone and 4 patients had 255 
both local and distant metastasis. Table 4 describes the site of recurrence stratified 256 
according to surgical approach. Surgical bed, bone and lymph node were the most 257 
common sites of local recurrence for both ORC and iRARC. Site of metastatic 258 
recurrence varied, with a predisposition of lung and liver metastasis in the ORC cohort. 259 
In addition, in the ORC cohort there were one para-umbilical hernia site, one skin and 260 
one penile metastasis while in the iRARC cohort; there were one port site recurrence 261 
and one penile metastasis.  262 
4. Discussion  263 
The results of the present study suggest that short term oncological outcomes for 264 
iRARC, including RFS and OS, are not inferior to those of ORC. This is consistent with 265 
the findings of the recent Pasadena Consensus Group where a number of retrospective 266 
case series from high-volume institutions were examined and it was suggested that 267 
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intermediate oncological outcomes for extracorporeal RARC are similar to those of ORC 268 
(5). However, data on oncological outcomes of intracorporeal RARC are limited as the 269 
technique has not been widely adopted due to its technical challenges.   270 
Tyritzis et al. and Desai et al. reported a 24 month RFS of 80.7% and 79% and an OS 271 
of 88.9% and 82.0% respectively in their iRARC series (2, 8). Desai et al. included 272 
patients from Tyritzis et al., hence the similarity in their results. We report a similar 24 273 
month RFS rate of 78.8% and an OS rate of 83.8%. However, there were a higher 274 
proportion of ≥pT3, and a lower proportion of pT2 tumors at final cystectomy pathology 275 
in the present series when compared in the present series than either Desai et al, or 276 
Tyritzis et al’s cohorts. This is surprising, as the present cohort describes a higher NAC 277 
uptake, in addition to a reduced proportion of patients with post-operative pT0 (22.5% 278 
vs 24.3-26.1%). Post cystectomy down-staging due to NAC is a well reported predictor 279 
of improved outcome and those who are ≥pT2 at cystectomy despite NAC are in fact 280 
non-responders with associated adverse oncological outcomes (15). Such an 281 
observation coupled with the present cohort’s oncological staging might suggest that 282 
this cohort of patients have more adverse pathological characteristics compared to 283 
Tyritzis et al. and Desai et al. (2, 8). 284 
In the present series, among the iRARC group there were significantly more patients 285 
who received a continent urinary diversion compared to patients who underwent ORC 286 
reflecting that a minimally invasive approach does not preclude orthotopic bladder 287 
reconstruction. In addition, there was a significant higher positive surgical margin rate in 288 
the ORC cohort, which might be explained by a higher proportion of patients with T4 289 
tumors in this group. 290 
Proponents of ORC have concerns that RARC patients might not receive as adequate a 291 
lymph node dissection compared to their ORC counterparts. However, similarly to Nix et 292 
al., we did not observe a difference between lymph node yield of our ORC and iRARC 293 
cohorts (16). This is an important point because although prognosis from nodal 294 
metastasis is poor, patient with localized bladder cancer with isolated nodal disease 295 
may be cured by surgery alone if an adequate lymphadenopathy is performed (17). In 296 
any curative cancer surgery, oncological outcomes are of paramount importance 297 
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especially where there are limited options for adjuvant treatment in bladder cancer (18). 298 
It is therefore encouraging that no significant difference in OS and RFS between ORC 299 
and iRARC was found in this study although there was a trend towards better OS in 300 
iRARC patients. 301 
Although there was no difference in lymph node yield, the lymph node count for both 302 
ORC and iRARC were lower compared to contemporary series (2, 8). This could be due 303 
to interobserver variability and the fact we did not perform an extended 304 
lymphadenectomy. Currently, there is no conclusive evidence to support extended  305 
lymph node dissection. Results of phase III South West Oncology Group (SWOG) 306 
S1011 trial and German Association of Urologic Oncology trial where patients are 307 
randomized to either extended or standard lymph node dissection are eagerly awaited.  308 
One concern that has been raised by bladder cancer surgeons regarding minimal 309 
invasive techniques, particularly intracorporeal reconstruction techniques, is the 310 
potential for port-site metastases and intraperitoneal seeding. Several plausible 311 
hypotheses for such occurrences have been suggested including seeding during 312 
extraction of the tumor, contact with contaminated laparoscopic instruments, and the 313 
effects of pneumoperitoneal desufflation (19-21). The recent retrospective analysis 314 
performed by Nguyen et al. suggested that patients treated with extracorporeal RARC 315 
had higher rates of extrapelvic lymph node recurrence [10/43 (23%) vs 4/26 (15%)] and 316 
peritoneal carcinomatosis [9/43 (21%) vs 2/26 (8%)] compared to ORC (9). They 317 
hypothesized that the robotic technique may result in altered lymphatic metastatic 318 
dissemination although they acknowledge this remains unproven. Eight of nine of 319 
patients with peritoneal carcinomatosis had ≥pT3 disease suggesting advanced 320 
disease. It would be interesting to know if patients with extrapelvic lymph node 321 
recurrence had pre-existing lymph node positive at cystectomy as this will make them at 322 
risk of lymph node recurrence. Analysis of data from the present study found no 323 
significant difference in the rate of local or metastatic RFS between ORC and iRARC 324 
groups. Of interest, in the iRARC series there were one port site recurrences and one 325 
penile metastasis; and in the ORC series, there was one case of recurrence in a para-326 
umbilical hernia, penis and skin. 327 
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Our data suggests that regardless of the modality of surgery the potential for the 328 
development of subcutaneous metastasis may in fact reflect tumor biology rather than 329 
surgical technique. Our findings are supported by a review by Kadi et al. which has 330 
reported that although rare, laparoscopic and open techniques carry a similar risk of 331 
subcutaneous metastasis, and that tumor grade and stage are probably more important 332 
in predicting the occurrence of subcutaneous metastasis in this setting (22).        333 
Certain limitations of the present study should be acknowledged, including the 334 
retrospective data collection. In addition, given the non-randomized nature of our study, 335 
differences in patient demographics, temporal patterns of referral and treatment as well 336 
as the nature of the tumors selected for a particular approach between the ORC and 337 
RARC groups are almost inevitable. Although there will be some inherent selection bias, 338 
since its introduction iRARC has been the default operation of choice at our institution, 339 
notwithstanding specific and contraindications to minimally invasive surgery, such as 340 
previous complex abdominal surgery. A difference in post-operative pathological tumor 341 
stage between ORC and iRARC was noted, which may be explained by stage migration 342 
as a result of a higher use of NAC in the iRARC cohort (RARC: 34.4% vs ORC: 23.0%). 343 
In this series, there was a trend towards significance between pT0 status and 344 
preoperative chemotherapy (preoperative chemotherapy: 23.1% vs no preoperative 345 
chemotherapy: 12.9%; p=0.087). This is evident in the higher proportion of ≤pT1 and 346 
pT0 patients in our iRARC cohort and confirmed by the fact that there were significantly 347 
more patients who were down-staged in the iRARC cohort (ORC: 17.4%; n=4/23 vs 348 
RARC: 51.6%; n=16/31) (p=0.01). Multivariate analysis was performed to attempt to 349 
account for other confounding variables although this is by no means a replacement of 350 
a randomize control trial. Additionally, our median follow-up in the RARC group was 351 
relatively short at 16.1 months. 352 
 353 
 354 
 355 
 356 
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5. Conclusions  357 
The findings of this study suggest that iRARC has comparable short term oncological 358 
outcomes, and similar site of metastatic and local recurrence compared to ORC. 359 
However, the results for higher stage (≥pT2) disease should be interpreted with caution 360 
in view of the increased use of NAC in the iRARC group. Hence, results of larger 361 
prospective randomized studies, such as the RAZOR trial are eagerly awaited to 362 
support our findings of the oncological equivalence of iRARC to ORC (23). 363 
 364 
   365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
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 378 
 379 
 380 
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Table 1: Patient demographic data and pathological characteristics for ORC and iRARC  461 
  462 
Characteristic  
ORC 
(n=94) 
iRARC 
(n=90) 
P value 
Gender Male 68 (72.3) 69 (76.7) 0.502 
 Female 26 (27.7) 21 (22.3)  
Age Mean ± SD 66.4 ±10.6 64.3 ± 12.3 0.290 
Type of tumour Urothelial cell 84 (89.4) 80 (88.9) 0.274 
 Squamous cell 6 (6.4) 7 (7.8)  
 Adenocarcinoma 4 (4.2) 1 (1.1) 
 
 Other 0 (0) 2 (2.2) 
Salvage cystectomy Yes 7 (7.4) 3 (3.3) 0.330 
 No 87 (92.6) 87 (96.7)  
Pre-cystectomy staging Carcinoma in situ 1 (1.1) 5 (5.6) 0.191 
 pTa 9 (9.6) 5 (5.6) 
 
 pT1 23 (23.4) 29 (32.2) 
 
pT2 
pT3 
pT4 
45 (47.9) 
14 (14.9) 
3 (3.2) 
42 (46.7) 
8 (8.9) 
1 (1.1) 
Tumour grade Carcinoma in situ 1 (1.0) 5 (5.6) 0.207 
 G2 7 (7.4) 4 (4.4) 
  G3 77 (81.1) 71 (78.9) 
 Non TCC 10 (10.5) 10 (11.1) 
Preoperative chemotherapy Yes 21 (22.3) 31 (34.4) 0.073 
 No 73 (77.7) 59 (65.6)  
Postoperative radiotherapy 
Yes  
No 
2 (2.1) 
92 (97.9) 
4 (4.4) 
86 (95.6) 
0.376 
Postoperative chemotherapy 
Yes 
No 
7 (7.4) 
87 (92.6) 
9 (10.0) 
81 (90.0) 
0.539 
Diversion type Ileal conduit 81 (86.2) 60 (66.6)       0.001 
 Continent 13 (13.8) 30 (33.4)  
Post-cystectomy stage pT0 8 (8.5) 20 (22.2) 0.001 
 Cis, pTa, pT1 25 (26.6) 35 (38.9) 
 
 pT2 22 (23.4) 8 (8.9) 
 pT3 23( 24.4) 23 (25.6) 
 pT4 16 (17.0) 4 (4.4) 
pT0 status pT0 8 (8.5) 20 (22.2) 0.025 
 Disease present 86 (91.5) 70 (77.8)  
Lymph node status Positive 18 (21.2) 13 (14.4) 0.229 
 Negative 67 (78.8) 77 (85.6)  
Number of lymph nodes 
Mean ± SD 
Range 
12.6±10.9 
0-48 
14.9±10.0 
0-51 
0.461 
Soft tissue surgical margin Positive 17 (19.3) 6 (8.2) 0.042 
 negative 71 (80.7) 67 (91.8)  
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ORC: open radical cystectomy; iRARC: intracorporeal robotic assisted radical 463 
cystectomy464 
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Table 2: Cox regression analysis comparing variables and recurrence free survival 465 
 466 
Variables P value 
Hazard 
ratio 
95% CI 
Technique (ORC vs iRARC) 0.799 1.09 0.58-2.02 
Surgical margin ( - vs + ) 0.217 1.62 0.75-3.50 
Perioperative chemotherapy 
(no vs yes) 
0.138 0.60 0.31-1.18 
Cystectomy pathological stage  
(≤pT2 vs ≥pT3) 
0.002* 3.38 1.57-7.26 
Node positive disease (N0 vs N1-3) 0.010* 2.56 1.25-5.23 
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ORC: open radical cystectomy; iRARC: intracorporeal robotic assisted radical 468 
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Table 3: Cox regression analysis comparing variables and cancer specific survival 485 
 486 
 487 
Variables P value 
Hazard 
ratio 
95% CI 
Technique (ORC vs iRARC) 0.639 1.20 0.56-2.55 
Surgical margin ( - vs + ) 0.236 1.65 0.72-3.76 
Perioperative chemotherapy 
(no vs yes) 
0.395 0.72 0.36-1.54 
Cystectomy pathological stage  
(≥pT3 vs ≤pT2) 
0.001* 7.08 2.39-21.00 
Node positive disease (N0 vs N1-3) 0.022* 2.45 1.14-5.29 
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Table 4: Cox regression analysis comparing variables and overall survival  511 
 512 
 513 
Variables P value 
Hazard 
ratio 
95% CI 
Technique (ORC vs iRARC) 0.624 1.19 0.601-2.34 
Surgical margin ( - vs + ) 0.281 1.53 0.71-3.31 
Perioperative chemotherapy 
(no vs yes) 
0.417 0.75 0.37-1.51 
Cystectomy pathological stage  
(≥pT3 vs ≤pT2) 
<0.001* 4.64 1.97-10.95 
Node positive disease (N0 vs N1-3) 0.020* 2.31 1.24-4.69 
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Table 5: Site of recurrence of patients with transitional cell carcinoma stratified 528 
according to ORC and iRARC  529 
Site of recurrence  Site of recurrence ORC 
N  
iRARC 
N 
Number of patients 
with recurrence: 
  
All sites 
Local 
Distant 
Local and distant 
30  
9  
13  
8  
17  
7  
6  
4  
Local recurrence site Bone 
Lymph nodes  
Surgical bed   
5 
6 
10 
3 
5 
8 
Distant recurrence site Adrenal 
Brain 
Bone 
Liver 
Lung 
Lymph nodes 
Mesentery/peritoneum  
Paraumbilical hernia  
Port site 
Penile  
Scalp/ skin  
1 
2 
4 
8 
8 
2 
3 
1 
0 
1 
1 
0 
0 
3 
1 
3 
3 
2 
0 
1 
1 
0 
 530 
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